Dogwood Therapeutics (DWTX) Non-Current Deferred Tax Liability (2023 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Non-Current Deferred Tax Liability of $11.9 million for Q1 2026, up 3.41% year-over-year from $11.5 million in Q1 2025, and down 1.66% quarter-over-quarter from $12.1 million in Q4 2025.
Dogwood Therapeutics (DWTX) Non-Current Deferred Tax Liability (2023 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $11.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability rose 3.41% year-over-year to $11.9 million; the TTM figure through Mar 2026 stood at $11.9 million (up 3.41% YoY), while the FY2025 annual figure was $12.1 million, up 7.02% from the prior year.
- Non-Current Deferred Tax Liability eased to $11.9 million in Q1 2026 per DWTX's latest filing, from $12.1 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $12.1 million in Q2 2025 and bottomed at $215622.0 in Q4 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $10.2 million across 4 years, with a median of $11.9 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability surged 5147.57% — and 2026, when it rose 3.41%.
- Dogwood Therapeutics' Non-Current Deferred Tax Liability stood at $215622.0 in 2023, then soared by 5147.57% to $11.3 million in 2024, then climbed by 7.02% to $12.1 million in 2025, then dropped by 1.66% to $11.9 million in 2026.
- Business Quant data shows DWTX's Non-Current Deferred Tax Liability at $11.9 million in Q1 2026, $12.1 million in Q4 2025, and $11.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.91 Mn |
| Mar 31, 2026 | 11.91 Mn |
| Dec 31, 2025 | 12.11 Mn |
| Dec 31, 2025 | 12.11 Mn |
| Sep 30, 2025 | 11.89 Mn |
| Sep 30, 2025 | 11.89 Mn |
| Jun 30, 2025 | 12.13 Mn |
| Jun 30, 2025 | 12.13 Mn |
| Mar 31, 2025 | 11.52 Mn |
| Mar 31, 2025 | 11.52 Mn |
| Dec 31, 2024 | 11.31 Mn |
| Dec 31, 2024 | 11.31 Mn |
| Dec 31, 2023 | 215,622.00 |
| Dec 31, 2023 | 215,622.00 |